TY - JOUR
T1 - Effectiveness and safety of bee venom pharmacopuncture for rheumatoid arthritis
T2 - A systematic review protocol
AU - Sung, Won Suk
AU - Kim, Jung Hyun
AU - Lee, Dong Hyuk
AU - Kim, Eun Jung
AU - Seo, Byung Kwan
AU - Hong, Seung Ug
AU - Baek, Yong Hyeon
AU - Lee, Kwang Ho
AU - Kim, Joo Hee
N1 - Funding Information:
Funding This study was supported by the Traditional Korean Medicine R&D programme funded by the Ministry of Health and Welfare through the Korea Health Industry Development Institute (KHIDI) (grant no. HF21C0077). Funder only provided the financial support and did not involve in this article including the review, editing or the submission for publication.
Publisher Copyright:
© Author(s) (or their employer(s)) 2022.
PY - 2022/3/14
Y1 - 2022/3/14
N2 - Introduction Rheumatoid arthritis (RA) is the common autoimmune disease with low quality of life. The representative treatment is medication and medication usage has improved through update of clinical guidelines, however, there are still limitations. Bee venom (BV) has been reported to have meaningful therapeutic effects and the possibility of alternative options for RA through several types of studies, but there is no well-organised and recent published systematic review (SR). Methods We will search randomised controlled trials about the BV on RA from the inception to 31 May 2022 in various databases, manual research and contacting authors. Electronic databases will include MEDLINE, EMBASE, Cochrane library, China National Knowledge Infrastructure, CiNii, J-STAGE, KoreaMed, Korean Medical Database, Korean Studies Information Service System, National Digital Science Library, Korea Institute of Science and Technology Information and Oriental Medicine Advanced Searching Integrated System. With screening and reviewing process, we will identify the eligible studies and extract the needed data. The primary outcome will be the disease activity scores indicating the improvement of RA symptoms (American College of Rheumatology response criteria 20, 50, 70), functions (Health Assessment Questionnaire, Disease Activity Score of 28 joints), joint (Western Ontario and McMaster universities osteoarthritis index), pain (Visual Analogue Scale, Numerical Rating Scale) and effective rate. The secondary outcomes will be the RA-related blood test levels and adverse events. We will perform a meta-analysis by Review Manager software, the assessment of risk of bias by Cochrane Collaboration ⠀˜ risk of bias' and the determination of quality of evidence by Grades of Recommendation, Assessment, Development and Evaluation. Ethics and dissemination Our SR will suggest the clinical evidence of the use of BV for RA to patient, clinicians and policymakers. We will publish our results in a peer-review journal.
AB - Introduction Rheumatoid arthritis (RA) is the common autoimmune disease with low quality of life. The representative treatment is medication and medication usage has improved through update of clinical guidelines, however, there are still limitations. Bee venom (BV) has been reported to have meaningful therapeutic effects and the possibility of alternative options for RA through several types of studies, but there is no well-organised and recent published systematic review (SR). Methods We will search randomised controlled trials about the BV on RA from the inception to 31 May 2022 in various databases, manual research and contacting authors. Electronic databases will include MEDLINE, EMBASE, Cochrane library, China National Knowledge Infrastructure, CiNii, J-STAGE, KoreaMed, Korean Medical Database, Korean Studies Information Service System, National Digital Science Library, Korea Institute of Science and Technology Information and Oriental Medicine Advanced Searching Integrated System. With screening and reviewing process, we will identify the eligible studies and extract the needed data. The primary outcome will be the disease activity scores indicating the improvement of RA symptoms (American College of Rheumatology response criteria 20, 50, 70), functions (Health Assessment Questionnaire, Disease Activity Score of 28 joints), joint (Western Ontario and McMaster universities osteoarthritis index), pain (Visual Analogue Scale, Numerical Rating Scale) and effective rate. The secondary outcomes will be the RA-related blood test levels and adverse events. We will perform a meta-analysis by Review Manager software, the assessment of risk of bias by Cochrane Collaboration ⠀˜ risk of bias' and the determination of quality of evidence by Grades of Recommendation, Assessment, Development and Evaluation. Ethics and dissemination Our SR will suggest the clinical evidence of the use of BV for RA to patient, clinicians and policymakers. We will publish our results in a peer-review journal.
KW - complementary medicine
KW - pain management
KW - rheumatology
UR - http://www.scopus.com/inward/record.url?scp=85126714339&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2021-056545
DO - 10.1136/bmjopen-2021-056545
M3 - Review article
C2 - 35288390
AN - SCOPUS:85126714339
VL - 12
JO - BMJ Open
JF - BMJ Open
SN - 2044-6055
IS - 3
M1 - e056545
ER -